Topics

Clinical Trials About "Next-generation Sequencing in Gastric Cancer to Evaluation Prognosis" RSS

12:48 EDT 30th March 2020 | BioPortfolio

We list hundreds of Clinical Trials about "Next-generation Sequencing in Gastric Cancer to Evaluation Prognosis" on BioPortfolio. We draw our references from global clinical trials data listed on ClinicalTrials.gov and refresh our database daily.

More Information about "Next-generation Sequencing in Gastric Cancer to Evaluation Prognosis" on BioPortfolio

We have published hundreds of Next-generation Sequencing in Gastric Cancer to Evaluation Prognosis news stories on BioPortfolio along with dozens of Next-generation Sequencing in Gastric Cancer to Evaluation Prognosis Clinical Trials and PubMed Articles about Next-generation Sequencing in Gastric Cancer to Evaluation Prognosis for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Next-generation Sequencing in Gastric Cancer to Evaluation Prognosis Companies in our database. You can also find out about relevant Next-generation Sequencing in Gastric Cancer to Evaluation Prognosis Drugs and Medications on this site too.

Showing "Next generation Sequencing Gastric Cancer Evaluation Prognosis" Clinical Trials 1–25 of 42,000+

Extremely Relevant

Next-generation Sequencing in Gastric Cancer to Evaluation Prognosis

Liquid biopsy has been widely used in the diagnosis and treatment of tumors, and cfDNA has always been a hot spot in clinical research. Previous studies have shown that cfDNA may be associated with postoperative recurrence of gastric cancer, but it is rarely reported whether cfDNA is associated with the survival of gastric cancer. The purpose of this study was to assess the relationship between cfDNA and survival in advanced gastric cancer


Predicting Biomarker of Gastric Cancer Chemotherapy Response

- discovery and validation of biomarker predicting gastric cancer chemotherapy response - Analysis for expression level of mRNA using Next generation sequencing in gastric cancer tissue by chemotherapy response - Analysis for expression level of miRNA using Next generation sequencing in gastric cancer tissue and blood by chemotherapy response - Validation of mRNA and miRNA using qRT-PCR in multiple independent cohort - B...

Research for Associated Genes for Gastric Cancer in Family Member With Affected First-Degree Relatives

Familial gastric cancer accounts for 10% of all cases, but predisposing genetic variations is unknown except for CDH1 mutation. Because Germline mutation is believed to be a key aspect of cancer predisposition, we plan to recruit persons with 2 or more affected family members in three-generation pedigree. The investigators will perform a whole-exome sequencing using DNA from blood samples of families including gastric cancer patients and non-gastric cancer patients


Development of Biomarker for the Evaluation of Response After Neoadjuvant Therapy in Patients With Pancreatic Cancer

The purpose of this study is to identify and apply biomarkers that can provide better information than previous imaging and blood tests when evaluating the response after neoadjuvant chemotherapy in pancreatic cancer patients who require neoadjuvant therapy before surgery.

Molecular Profiling to Improve Outcome of Patients in Cancer. A Pilot Study

Next Generation Sequencing in cancer: a feasibility study in France to assess sample circuit and to perform analyzes within a limited time.

Diagnosis of Lynch Syndrome Based on Next-generation Sequencing in Colorectal Cancer

The purpose of this study is to determine the proportion of patients diagnosed with Lynch syndrome in colorectal cancer patients with the loss of staining by immunohistochemistry (IHC) of any of the mismatch repair (MMR) proteins. Besides, this study aims to test the specificity and the sensitivity of detecting microsatellite instability (MSI) by next-generation sequencing, and to find out the consistency between IHC and MSI in colorectal cancer patients in China. In addition, ...

Evaluation of Efficacy and Toxicity of Nivolumab Monotherapy for Advanced Non-small Cell Lung Cancer After First-line Treatment Failure Based on Second-generation Sequencing and Liquid Chip Platform

In order to understand the efficacy and side effects of lung cancer immunotherapy, at least 30 patients with lung cancer who were treated with immunotherapy were enrolled. The second-generation sequencing technology and liquid phase factor platform were used for detection, and clinical imaging and other evaluation methods were used to explore the immunotherapy efficacy and side effects affecting lung cancer。

Application of NGS Technique in Precise Diagnosis of Infectious Diseases

Infectious disease leads to deaths that accounted for more than 25% of all causes of human mortality. But the traditional microbiological diagnostic methods such as specimen culture are sometimes time-consuming, and have limited sensitivity. And some bacteria, anaerobes and viruses may be difficult to cultivate and isolation. Therefore, the accurate identification and rapid classification of pathogenic microorganisms is very important for the patient's precise diagnosis and tim...

Next Generation Sequencing(NGS)Monitors Minimal Residual Disease(MRD)in Allo-PBSCT Patients

Objective: to evaluate the value of high-throughput next generation gene sequencing (NGS) in the detection of minimal residual disease (MRD) and recurrence after allogeneic transplantation. Overview of study design. This study is a single-center, single-arm, prospective clinical trial designed to evaluate the significance of next generation gene sequencing (NGS) in monitoring for minimal residual disease (MRD) and recurrence after allogeneic transplantation. This ...

Relevant

Enhancing Diagnosis in Chronic B-cell Lymphoproliferative Disorders Using Next-Generation Sequencing

To enhance the diagnosis of unclassifiable, non-CLL B-LPDs using next-generation sequencing technology.

Genomic Sequencing and Personalized Treatment for Birth Defects in Neonatal Intensive Care Units

The purpose of study is to evaluate the benefits of using the Next Generation Sequencing Technology to diagnose birth defects and genetic diseases. The results from genomic sequencing can also significantly shorten the time of examination, improve the diagnosis rate, guide the clinical treatments. So the ultimate goal is individualized or personalized therapy and promote prognosis.

Genomic Sequencing and Personalized Treatment for Birth Defects in Neonatal Intensive Care Units

The purpose of study is to evaluate the benefits of using the Next Generation Sequencing Technology to diagnose birth defects and genetic diseases. The results from genomic sequencing can also significantly shorten the time of examination, improve the diagnosis rate, guide the clinical treatments. So the ultimate goal is individualized or personalized therapy and promote prognosis.

Gastric Cancer Prevention for Indigenous Peoples

The incidence of gastric cancer in local indigenous peoples is higher than the non-Indigenous counterpart in Taiwan. How to design an effective prevention strategy for gastric cancer is of importance. The present study aimed to identify the causes that may account for the health inequalities, allowing generation of a plan of action on the whole population scale.

Non-coding RNA in the Exosome of the Epithelia Ovarian Cancer

This study aims to analyze the expression of micro-RNA (miRNA) and long non-coding RNA (lncRNA) by next-generation sequencing in patients with high grade serous ovarian cancer (HGSOC) and benign gynecologic diseases. The candidate miRNA/lncRNA will be validated as biomarker for the detection and prognosis of HGSOC.

Sensitivity and Specificity of NGS in Detecting bMSI in Patients With Gastric, Duodenal and Small Intestinal Cancer

To study the sensitivity and specificity of NGS in detecting Microsatellite State in blood and to evaluate its potential application in gastrointestinal cancer.

A Validation Study of Relationships Among Genomic Gene Expression Profile, Prognosis and Prediction of Adjuvant Chemotherapy Benefit With Capecitabine and Oxaliplatin in Gastric Cancer Stage II and III (6th AJCC) Patients After D2 Surgery (CLASSIC)

The purpose of this study is to validate a pre-defined single-patient classifier algorithm for predicting prognosis and benefit from adjuvant chemotherapy for patients who underwent D2 gastrectomy for stage II and III gastric cancer. This algorithm classifies gastric cancer into five groups according to its molecular characteristics based on RNA expression levels. The prognosis and response from adjuvant chemotherapy will be different according to prognostic and predictive clus...

Personalized Therapy of Molecular Tumor Board Participation With the Guidance of Next Generation Sequencing

This study seeks to evaluate the clinical value of the personalized therapy model with the guidance of Molecular Tumor Board (MTB) after Next Generation Sequencing(NGS), and to track patient outcomes.

Dynamic Monitoring of ctDNA Methylation to Predict Relapse in Stage II-III Colorectal Cancer After Radical Resection

This is a prospective, multicenter, observational, single-blinded controlled study. Dynamic monitoring of patients with stage II-III colorectal cancer was performed using the previously established colorectal tumor-specific plasma ctDNA methylation markers (diagnostic model established by next-generation sequencing of 2181 gene loci methylation). The methylation marker had a sensitivity of 93% in colorectal cancer patients with a specificity of 99% in healthy individuals. Dynam...

Molecular Characterization of Acute Erythroid Leukemia (M6-AML) Using Targeted Next-generation Sequencing

Acute erythroid leukemia (AEL) is a morphologically distinct, infrequent (o5%) acute myeloid leukemia (AML) designed as M6 in the French- American-British (FAB) classification. The World Health Organization classification recognizes two subclasses, M6a, a leukemia with myeloid blast cells, and M6b, a very rare, purely erythroid AML. It may be difficult to distinguish between a myelodysplastic syndrome and AEL because of the erythroblastic proliferation, which is increased when ...

Delineation of Novel Monogenic Disorders in the United Arab Emirates Population

The study aims to identify novel monogenic phenotypes from specific pedigrees and discover the underlying causal genetic variant using genetic sequencing (Sanger and/or Next Generation Sequencing - Panel/WES/WGS) methodologies in families across the United Arab Emirates (UAE).

Comparing the Prognosis of Patients With Cardia and Non-cardia Gastric Cancer.

To comparing the stage-for-stage prognosis of patients with cardia and non-cardia gastric cancer after operation.

Lung Cancer Next Generation Sequencing Using the Oncomine Comprehensive Assay

Currently, publicly funded standard of care testing in Ontario for stage IV lung cancer patients uses individual gene tests to look for mutations in the EGFR and ALK genes. This testing broadens treatment options for patients, however there are other gene mutations with corresponding targeted treatments that are not routinely tested for. This study will evaluate the utility and added value of using a next generation sequencing (NGS) panel, the Oncomine Comprehensive Assay v3, t...

Next Generation Pathogen Sequencing for Prediction of Adverse Events

The majority of children and adolescents diagnosed with cancer will experience one or more episodes of fever or infection during their course of therapy. The most common microbiologically documented infection is bloodstream infection (BSI), which can be associated with severe sepsis or death. Current methods of diagnosis require a significant load of live bacteria in the blood making early detection difficult. Delayed diagnosis and delayed optimal therapy of BSIs are associated...

Swallowable Sponge Cell Sampling Device and Next Generation Sequencing in Detecting Esophageal Cancer in Patients With Low or High Grade Dysplasia, Barrett Esophagus, or Gastroesophageal Reflux Disease

This pilot clinical trial studies how well a swallowable sponge cell sampling device and next generation sequencing work in detecting esophageal cancer in patients with low or high grade dysplasia, Barrett esophagus, or gastroesophageal reflux disease. Checking biomarkers in abnormal esophageal cells using a swallowable sponge cell sampling device and next generation sequencing may improve diagnosis and treatment of esophageal cancer.

Detect Microsatellite Instability Status in Blood Sample of Advanced Colorectal Cancer Patients by Next-Generation Sequencing

The method to analyze the microsatellite instability (MSI) status by next-generation sequencing (NGS) has been established to assess the deficiency of DNA mismatch repair (MMR) system. The aim of our study is to evaluate the feasibility and reliability of this NGS method by testing the circulating tumor DNA (ctDNA) in blood sample of advanced colorectal cancer patients. If the result is positive, the MSI status could be easily learned without the acquisition of tissue samples.


More From BioPortfolio on "Next-generation Sequencing in Gastric Cancer to Evaluation Prognosis"

Quick Search